Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising
effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of
standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically
inhibits VEGFR-2. This study summarizes the experience of three Peking University affiliated
hospitals in off-label use of apatinib in the treatment of extensively pre-treated sarcoma.
Phase:
N/A
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Peking University International Hospital Peking University Shougang Hospital